Outcomes of Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma Patients at a Tertiary Referral Centre
Publish place: Middle East Journal of Cancer، Vol: 14، Issue: 2
Publish Year: 1402
نوع سند: مقاله ژورنالی
زبان: English
View: 48
This Paper With 11 Page And PDF Format Ready To Download
- Certificate
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_MISJ-14-2_007
تاریخ نمایه سازی: 25 آبان 1402
Abstract:
Background: Autologous stem cell transplant (ASCT) has been used as a consolidative treatment modality in non-Hodgkin’s lymphoma (NHL), but its role in NHL management is still evolving. The study aimed to evaluate the patient outcomes based on age, NHL subtypes, and conditioning regimen.Method: We performed a retrospective analysis of NHL patients who received ASCT (n = ۱۴۰) in our centre from ۱۹۹۲-۲۰۱۵. Data were gathered for this investigation using electronic records and case notes. Refractory illness, relapse, progressive disease, or death were all considered progression events. Time from ASCT to the last follow-up or progression event was used to define progression-free survival (PFS), and time from ASCT to death or the final follow-up was used to define overall survival (OS).Results: Median age at ASCT was ۵۵ years (۱۶-۶۸). Amongst patients ≤۶۰ years (n = ۱۰۹) and >۶۰ years (n = ۳۱), there was no significant difference in PFS (P = ۰.۷۵۶), OS (P = ۰.۷۱۱), neutrophil (۱۲.۵ vs. ۱۱ days) and platelet (۱۲ vs. ۱۴ days) engraftment times. Amongst follicular lymphoma patients (n = ۵۴) who received BEAM (carmustine, etoposide, cytarabine, melphalan) (n = ۳۰) or Cy/TBI (cyclophosphamide/ total body irradiation) (n=۲۴) conditioning, there was no significant difference between PFS (P = ۰.۱۱۱) and OS (P = ۰.۶۶۷). There was no significant difference (P = ۰.۴۶) in the incidence of second malignancies in the patient receiving BEAM or TBI-based conditioning.Conclusion: ASCT can be safely performed for NHL in patients >۶۰ years with outcomes similar to those ≤۶۰ years. TBI based conditioning appear safe with similar outcomes to BEAM in follicular lymphoma patients. Prospective studies are needed to confirm these findings.
Keywords:
Authors
Ajay Prakash
Division of Oncology, Saskatchewan Cancer Agency, College of Medicine, University of Saskatchewan, Regina, Canada
Hugh Goodman
Department of Hematology, Waikato Hospital, Hamilton, New Zealand
مراجع و منابع این Paper:
لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :